We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 1,138

Mayo on the side? The Canadian Patent Office issues new examination guidelines for medical diagnostic methods
  • Borden Ladner Gervais LLP
  • Canada
  • July 17 2015

On June 29, 2015, the Canadian Intellectual Property Office (CIPO) issued a long-awaited Practice Notice PN 2015-02("Notice") on the subject of


Court of Appeal gives guidance on sound prediction issues
  • Borden Ladner Gervais LLP
  • Canada
  • July 15 2015

The Federal Court of Appeal (FCA) upheld a recent infringement decision finding a patent to be invalid due to inutility (decision here; summary here


Federal Court of Appeal reinterprets product specificity requirements: patent listing is determined by patent claims construction and not a word match
  • Gowling Lafleur Henderson LLP
  • Canada
  • July 23 2015

On July 17, 2015, the Federal Court of Appeal set aside a judgment of the Federal Court that upheld Health Canada’s refusal to list Canadian Patent 2


Pharma in brief - Apotex Inc. and Apotex Pharmachem Inc. are ordered to disgorge profits in excess of $61 million
  • Norton Rose Fulbright Canada LLP
  • Canada
  • July 10 2015

Apotex Inc. (Apotex) and Apotex Pharmachem Inc. (Pharmachem) have been ordered by the Federal Court to pay to Adir and Servier Canada


Pharma in brief - Federal Court applies principle of claim differentiation and rejects elevated “promise” of utility for compound claims
  • Norton Rose Fulbright Canada LLP
  • Canada
  • July 8 2015

O’Reilly J. granted a prohibition order sought by Novartis Pharmaceuticals Canada Inc. (Novartis) under section 6 of thePM(NOC) Regulations against


Listing patents against combination drugs in Canada ? Changes coming
  • Gowling Lafleur Henderson LLP
  • Canada
  • December 1 2014

On Nov. 26, 2014, Industry Canada announced an important proposed change to the eligibility requirements for listing a patent against a drug in


Teva v Pfizer, or the “Viagra saga”: if there is no quid proper disclosure there can be no quo exclusive monopoly rights
  • Fasken Martineau DuMoulin LLP
  • Canada
  • November 19 2012

Sildenafil is the active ingredient in Viagra, the blockbuster potency-enhancing drug marketed by Pfizer


Proposed PMNOC Regulations amendments published for comment following dismissal of Viiv appeal re: listing claim for medicinal ingredient against fixed-dose combination
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • May 4 2015

As we previously reported, Viiv's application against Teva for a prohibition Order regarding a combination product containing abacavir and lamivudine


IP monitor - a controversial diagnosis: new patent examination guidance in Canada for evaluating diagnostic methods
  • Norton Rose Fulbright Canada LLP
  • Canada
  • July 7 2015

On June 29, 2015, the Canadian Intellectual Property Office issued guidance to patent examiners on examining patent applications for medical


Federal court grants accounting of profits and addresses NIA “non-infringing alternative”
  • Gowling Lafleur Henderson LLP
  • Canada
  • July 10 2015

The Federal Court recently released a decision Accounting for an infringer's profits in a pharmaceutical matter (ADIR and Servier Canada Inc. v